Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1583MR)

This product GTTS-WQ1583MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1583MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7806MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ6963MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ668MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ12125MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ5095MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ1918MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ5990MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ14414MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO 24-7375
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW